Freespira is a breakthrough treatment that normalizes CO2 and respiratory rates in a single 28-day treatment for adults and adolescents*, resulting in significant reductions in symptoms, high remission rates and significantly lower total medical costs. Health plans, providers and self-insured employers use Freespira to improve quality of life and to support the appropriate use of valuable healthcare resources.
We are pleased with the clinical and financial outcomes that we’ve achieved for our health plan members with PTSD and panic disorder through the use of Freespira. This breakthrough drug-free treatment approach has reduced the impact of symptoms associated with panic disorder and PTSD resulting in reduced use of medications and other healthcare costs for symptom management.”
~ Demetrios C. Marousis, MA, MBA, LPC
Director, Behavioral Health
Panic Attack Costs Are Reduced With Freespira.
86%1 of Freespira users were panic attack-free immediately post treatment, and 79%2 were panic attack-free 1 year post treatment.
*Freespira is indicated (FDA-cleared) as an adjunctive treatment of symptoms associated with panic disorder, panic attacks and/or PTSD in patients 18 and older. In younger patients, Freespira has been evaluated and is being made available as permitted by FDA’s COVID-19 Enforcement Discretion Guidance.
1 Vol.:(0123456789)1 3 Applied Psychophysiology and Biofeedback https://doi.org/10.1007/s10484-020-09465-0, Evaluating the Impact of Freespira on Panic Disorder Patients’ Health Outcomes and Healthcare Costs within the Allegheny Health Network, Alicia Kaplan · Anthony P. Mannarino · P. V. Nickell.
2 Tolin DF, et al., Appl Psychophysiology Biofeedback. 2017; 42:51-58.
3 Ostacher MJ*, Investigation of the Freespira System in the treatment of PTSD.
†Reduced costs are anticipated based on panic attack and panic disorder results.